Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1

Conditions

Virus Diseases 1Sexually Transmitted Diseases 1Papillomavirus Infections 1Keratosis, Actinic 1Condylomata Acuminata 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 280Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × Therapies, Investigational × Clear all
NCT02404389 2021-01-05

Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients

Novartis

Phase 2 Completed
82 enrolled 16 charts
Dermatologic

Keratosis, Actinic

NCT02482428 2021-01-05

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

Novartis

Phase 2 Completed
88 enrolled 10 charts

Condylomata Acuminata, Sexually Transmitted Diseases, Virus Diseases, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡